Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer

Eur Urol. 2019 Nov;76(5):604-606. doi: 10.1016/j.eururo.2019.07.034. Epub 2019 Jul 27.

Authors

Nils O Elander¹, Syed A Hussain²

Affiliations

¹ Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
² Department of Oncology and Metabolism, Academic Oncology Unit, University of Sheffield Medical School, Sheffield, UK. Electronic address: syed.hussain@sheffield.ac.uk.

PMID: 31358380
DOI: 10.1016/j.eururo.2019.07.034

No abstract available

Publication types

Editorial
Comment

MeSH terms

B7-H1 Antigen
Humans
Mutation
Programmed Cell Death 1 Receptor
Receptor, Fibroblast Growth Factor, Type 3 / genetics
Urinary Bladder Neoplasms*

Substances

B7-H1 Antigen
Programmed Cell Death 1 Receptor
FGFR3 protein, human
Receptor, Fibroblast Growth Factor, Type 3